The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy
Established in June 2017, VALIDATE is an international network of researchers working to accelerate vaccine development for four neglected intracellular pathogens that cause significant mortality and morbidity globally: Mycobacterium tuberculosis, Leishmania spp., Burkholderia pseudomallei and Mycob...
Main Authors: | , , |
---|---|
Format: | Book section |
Language: | English |
Published: |
Springer
2023
|
_version_ | 1797112108423315456 |
---|---|
author | Vermaak, S Sampson, S McShane, H |
author_facet | Vermaak, S Sampson, S McShane, H |
author_sort | Vermaak, S |
collection | OXFORD |
description | Established in June 2017, VALIDATE is an international network of researchers working to accelerate vaccine development for four neglected intracellular pathogens that cause significant mortality and morbidity globally: Mycobacterium tuberculosis, Leishmania spp., Burkholderia pseudomallei and Mycobacterium leprae. In 5 years, VALIDATE has grown to have more than 550 members from over 250 institutes across 72 countries and has had several successes and important outputs. This chapter discusses VALIDATE’s origins, achievements and future direction. |
first_indexed | 2024-03-07T08:19:33Z |
format | Book section |
id | oxford-uuid:040bcb5a-ff52-4e0e-ae11-1f53096a30cb |
institution | University of Oxford |
language | English |
last_indexed | 2024-03-07T08:19:33Z |
publishDate | 2023 |
publisher | Springer |
record_format | dspace |
spelling | oxford-uuid:040bcb5a-ff52-4e0e-ae11-1f53096a30cb2024-01-26T11:31:08ZThe VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosyBook sectionhttp://purl.org/coar/resource_type/c_1843uuid:040bcb5a-ff52-4e0e-ae11-1f53096a30cbEnglishSymplectic ElementsSpringer2023Vermaak, SSampson, SMcShane, HEstablished in June 2017, VALIDATE is an international network of researchers working to accelerate vaccine development for four neglected intracellular pathogens that cause significant mortality and morbidity globally: Mycobacterium tuberculosis, Leishmania spp., Burkholderia pseudomallei and Mycobacterium leprae. In 5 years, VALIDATE has grown to have more than 550 members from over 250 institutes across 72 countries and has had several successes and important outputs. This chapter discusses VALIDATE’s origins, achievements and future direction. |
spellingShingle | Vermaak, S Sampson, S McShane, H The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy |
title | The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy |
title_full | The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy |
title_fullStr | The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy |
title_full_unstemmed | The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy |
title_short | The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy |
title_sort | validate network accelerating vaccine development for tuberculosis leishmaniasis melioidosis and leprosy |
work_keys_str_mv | AT vermaaks thevalidatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy AT sampsons thevalidatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy AT mcshaneh thevalidatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy AT vermaaks validatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy AT sampsons validatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy AT mcshaneh validatenetworkacceleratingvaccinedevelopmentfortuberculosisleishmaniasismelioidosisandleprosy |